Last reviewed · How we verify
NCT00031174
Blood Component Collection From Patients With Rheumatic or Kidney Disease and Healthy Volunteers
trial in Rheumatic Diseases in 151 participants. Terminated before completion.
17 August 2020
Quick facts
| Lead sponsor | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 151 |
| Start date | 13 February 2002 |
| Primary completion | 17 August 2020 |
| Estimated completion | 17 August 2020 |
| Sites | 1 location across United States |
Conditions studied
- Rheumatic Diseases — all drugs for Rheumatic Diseases →
- Healthy Volunteers — all drugs for Healthy Volunteers →
Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Who can join
Adults 18 to 120, any sex, with Rheumatic Diseases or Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will collect white blood cells or plasma (the liquid part of the blood), or both, from healthy volunteers and from patients with rheumatic or kidney disorders for research purposes. Rheumatic disorders involve abnormalities of the immune system, the body s defense against disease. The immune system consists of white blood cells such as lymphocytes and monocytes, which produce substances such as antibodies and cytokines. White cells and plasma will be collected through a procedure called apheresis (described below). Healthy volunteers and patients with confirmed or suspected rheumatic or kidney disease who are 18 years of age or older may be eligible for this study. Patients must be participating in a current protocol of the National Institute of Arthritis and Musculoskeletal and Skin Diseases or the National Institute of Digestive, Diabetes and Kidney Diseases. All candidates will be screened with a history, physical examination, and blood tests for hepatitis B and C and HIV infection. Women of childbearing age will be tested for pregnancy. Routine blood tests will be done in all volunteers, and in patients where needed. Pregnant women and people who test positive for hepatitis or HIV may not participate. Participants will undergo apheresis to collect lymphocytes, monocytes, or plasma from the blood. For this procedure, a needle is placed in a vein in the arm. Blood flows from the vein through a tube (catheter) into a machine that spins the blood, separating it into its components. The required cells or plasma are extracted, and the rest of the blood, including the red cells and platelets, is returned to the body through the same needle or through a second needle placed in the other arm. Cells collected from volunteers will be used in studies comparing the number and function of similar cells from patients with rheumatic diseases, focusing on the differences in number and function of the cells in health and disease. Components collected from patients will be used only for studies described in the protocol in which they are currently enrolled. ...
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT00031174
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rheumatic Diseases
Currently open trials in the same condition.
- NCT07490041 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refr · EARLY_PHASE1 · recruiting
- NCT07350395 — Exploring and Measuring the Impact of Steroids in Children and Young People · recruiting
- NCT07278609 — The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions · recruiting
- NCT07148414 — A Study of SPY072 in Rheumatic Disease · Phase 2 · recruiting
- NCT06400628 — Effectiveness of Chronic Self-management Education on Behavioral and Clinical Outcomes · NA · recruiting
Other National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) trials
Trials by the same sponsor.
- NCT07012057 — Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis · Phase 2 · withdrawn
- NCT06238531 — A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus · Phase 1 · withdrawn
- NCT05440422 — The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN- · Phase 2 · recruiting
- NCT05738824 — Natural History of Inflammatory Muscle Diseases · recruiting
- NCT05567198 — Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Det · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00031174 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Last refreshed: 21 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00031174.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing